{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=capecitabine&page=22", "query": { "intervention": "capecitabine", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 760, "total_pages": 76, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=capecitabine&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=capecitabine&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T07:06:13.567Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00089479", "title": "A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "capecitabine [Xeloda]", "type": "DRUG" }, { "name": "Taxotere", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "18 Years to 70 Years · Female only" }, "enrollment_count": 2611, "start_date": "2002-08", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2012-12-21", "last_synced_at": "2026-10-27T07:06:13.567Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089479" }, { "nct_id": "NCT05629585", "title": "A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Dato-DXd", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 1174, "start_date": "2022-11-28", "completion_date": "2030-02-28", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-27T07:06:13.567Z", "location_count": 88, "location_summary": "Gilbert, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 70 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05629585" }, { "nct_id": "NCT02301143", "title": "Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Neoplasms" ], "interventions": [ { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Chemoradiation", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2015-04-21", "completion_date": "2018-04-26", "has_results": true, "last_update_posted_date": "2019-03-20", "last_synced_at": "2026-10-27T07:06:13.567Z", "location_count": 23, "location_summary": "Scottsdale, Arizona • Sacramento, California • San Diego, California + 20 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02301143" }, { "nct_id": "NCT06312176", "title": "A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Sacituzumab tirumotecan", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Liposomal doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1200, "start_date": "2024-04-14", "completion_date": "2031-04-12", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-27T07:06:13.567Z", "location_count": 46, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Fullerton, California + 38 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06312176" }, { "nct_id": "NCT00470184", "title": "Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "microarray analysis", "type": "GENETIC" }, { "name": "reverse transcriptase-polymerase chain reaction", "type": "GENETIC" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "biopsy", "type": "PROCEDURE" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "GENETIC", "PROCEDURE", "RADIATION" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2006-11", "completion_date": null, "has_results": true, "last_update_posted_date": "2013-11-25", "last_synced_at": "2026-10-27T07:06:13.567Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00470184" }, { "nct_id": "NCT00493636", "title": "1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accelerated Community Oncology Research Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2007-06", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2014-05-20", "last_synced_at": "2026-10-27T07:06:13.567Z", "location_count": 44, "location_summary": "Anchorage, Alaska • Fayetteville, Arkansas • Corona, California + 37 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Corona", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00493636" }, { "nct_id": "NCT04674306", "title": "Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer", "TNBC - Triple-Negative Breast Cancer", "Residual Disease" ], "interventions": [ { "name": "α-lactalbumin vaccine", "type": "BIOLOGICAL" }, { "name": "Zymosan", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "George T. Budd", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2021-10-01", "completion_date": "2025-12-29", "has_results": true, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-27T07:06:13.567Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04674306" }, { "nct_id": "NCT00763516", "title": "Proton Radiation for Resectable Carcinoma of the Pancreas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Proton radiation and chemotherapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2009-02", "completion_date": "2017-08-17", "has_results": false, "last_update_posted_date": "2017-09-06", "last_synced_at": "2026-10-27T07:06:13.567Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00763516" }, { "nct_id": "NCT04333706", "title": "A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast", "Metastatic", "Triple Negative", "Cancer", "Disseminated Tumor Cell" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Sarilumab 150mg or 200 mg plus Capecitabine", "type": "COMBINATION_PRODUCT" }, { "name": "Sarilumab 150mg plus Capecitabine", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 65, "start_date": "2020-09-26", "completion_date": "2027-05-03", "has_results": false, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-10-27T07:06:13.567Z", "location_count": 3, "location_summary": "Los Angeles, California • Gainesville, Florida", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04333706" }, { "nct_id": "NCT04456699", "title": "Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Leucovorin/ levoleucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 335, "start_date": "2020-08-19", "completion_date": "2023-11-06", "has_results": true, "last_update_posted_date": "2024-10-29", "last_synced_at": "2026-10-27T07:06:13.567Z", "location_count": 23, "location_summary": "Burbank, California • Fullerton, California • Colorado Springs, Colorado + 19 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Athens", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04456699" } ] }